MediPharm's Australia Subsidiary Debuts In Europe, Signs Supply Agreement
MediPharm's Australia Subsidiary Debuts In Europe, Signs Supply Agreement
The deal will last three years, during which Therismos is obligated to obtain specific formulations and dosage forms within the British Isles.Medicinal cannabis company MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF ) said Friday its Australian unit has agreed to a white-label supply deal with a subsidiary of Cannaray Ltd.
藥用大麻公司 醫藥實驗室股份有限公司 。(TSX: 實驗室) 醫療 週五，其澳大利亞單位已同意與 Cannaray 有限公司的一家子公司達成白標供應協議。
According to the deal, MediPharm Labs Australia Pty. Ltd will provide Cannaray’s Therismos Ltd. with a whole set of cannabis oil products.
根據這筆交易 醫療製藥實驗室澳大利亞 Pty。有限公 將為坎納瑞的 Therismos 有限公司提供一整套大麻油產品。
MediPharm's products are in accordance with the German Institute for Drugs and Medical Devices’ quality standards.
MediPharm 的產品符合德國藥物和醫療器械研究所的品質標準。
The deal will last three years, during which Therismos is obligated to obtain specific formulations and dosage forms within the British Isles.
這項交易將持續三年, 在此期間 Therismos 有義務獲得不列顛三島內的特定配方和劑型.
Cannaray is a London-based cannabis and lifestyle company that holds licenses to operate with controlled drugs across Europe.
Cannaray 是一家總部位於倫敦的大麻和生活方式公司，擁有在歐洲各地使用受管制藥物經營的許可證。
“With the growing recognition of CBD’s therapeutic benefits, Cannaray is in the right place at the right time with an outstanding product portfolio and a highly engaged team of professionals. We look forward to participating in their growth,” said MediPharm Labs CEO Pat McCutcheon.
「隨著對 CBD 治療效益的認可越來越多，Cannaray 憑藉出色的產品組合和高度參與的專業團隊，在正確的時間處於正確的地方。我們期待著參與他們的成長。」醫藥實驗室首席執行官帕特·麥卡特川（Pat McCutcheon）說。
Cannaray’s CEO Scott Maguire shares the enthusiasm, citing how “both of Labs’ production facilities have achieved GMP certification.” This will help the company reach the goal of providing patients with high-quality products, he explained.
坎納雷首席執行官斯科特·馬奎爾（Scott Maguire）分享了熱情，理由是「兩個實驗室的生產設施如何獲得 GMP 認證」。他解釋說，這將有助於該公司達到為患者提供高質量產品的目標。
The supply agreement comes on the heels of the closing of strategic manufacturing and IP licensing agreement between MediPharm Labs and Avicanna Inc (TSX: AVCN) (OTCQX:AVCNF).
供應協議是關於戰略製造和知識產權許可協議之間結束的後蹄 醫藥實驗室 和 艾维康纳 (TSX: 阿夫聯盟) (OTCQX: 阿夫 CNF).
According to the agreement, MediPharm Labs will utilize its Canada-based specialized production facility to manufacture Avicanna’s Rho Phyto medical cannabis products and Pura Earth topicals.
根據協議，MediPharm 實驗室將利用其總部位於加拿大的專業生產設施來生產 Avicanna 的 Rho Phyto 醫用大麻產品和 Pura Earth 專用藥。
The products will be available through Medical Cannabis by Shoppers.
該產品將通過購物者通過醫用大麻提供。
Under the three year deal, the Toronto-based biopharmaceutical leader is bound to provide MediPharm Labs with a license to use its formulations for further development of MediPharm Labs’ products.
根據為期三年的合約，這家總部位於多倫多的生物製藥領導者必定會為 MediPharm Labs 提供許可證，以使用其配方進一步開發 MediPharm 實驗室的產品。
Earlier this month, MediPharm Labs announced it expanded its footprint in New Zealand via its subsidiary.
本月初，MediPharm 實驗室宣布透過子公司擴大其在紐西蘭的業務版圖。
MediPharm Labs Australia has inked another supply agreement with Cannasouth (NZSD: CBD), a company focused on developing next-generation medicinal cannabis products.
澳大利亞醫藥實驗室簽署了另一項供應協議 河南 NZSD：CBD）是一家專注於開發下一代藥用大麻產品的公司。
譯文內容由第三人軟體翻譯。
